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Abstract
Background: Despite extensive research, no reliable biological marker for chronic fatigue syndrome (CFS) has yet
been identified. However, hyperactivation of melanotrophs in the pituitary gland and increased levels of plasma
alpha-melanocyte-stimulating hormone (a-MSH) have recently been detected in an animal model of chronic stress.
Because CFS is considered to be caused partly by chronic stress events, increased a-MSH plasma levels may also
occur in CFS patients. We therefore examined a-MSH levels in CFS patients.
Methods: Fifty-five CFS patients, who were previously diagnosed within 10 years of with the disease, were enrolled
in this study. Thirty healthy volunteers were studied as controls. Fasting bloods samples were collected in the
morning and evaluated for their plasma levels of a-MSH, adrenocorticotropic hormone (ACTH), serum cortisol and
dehydroepiandrosterone sulfate (DHEA-S). Mean levels of a-MSH were compared between the CFS and control
groups using Welch’s t test.
Results: The mean plasma a-MSH concentration in the CFS group (17.9 ± 1.0 pg/mL) was significantly higher than
that in healthy controls (14.5 ± 1.0 pg/mL, p = 0.02). However, there was a wide range of values in the CFS group.
The factors correlated with the plasma a-MSH values were analyzed using Spearman’s rank correlation. A negative
correlation was found between the duration of the CFS and the plasma a-MSH values (p = 0.04, rs = -0.28), but no
correlations with ACTH, cortisol or DHEA-S levels were identified (p = 0.55, 0.26, 0.33, respectively). The CFS patients
were divided into two groups: patients diagnosed for ≤ 5 years’ duration, and those diagnosed for 5-10 years’
duration. They were compared with the healthy controls using one-way ANOVA and Tukey-Kramer multiple
comparison tests. The mean a-MSH concentration in the ≤ 5 years group was 20.8 ± 1.2 pg/mL, which was
significantly higher than that in the healthy controls (p < 0.01). There was no significant difference between the
5-10 year group (15.6 ± 1.4 pg/mL) and the healthy controls.
Conclusions: CFS patients with a disease duration of ≤ 5 years had significantly higher levels of a-MSH in their
peripheral blood. a-MSH could be a potent biological marker for the diagnosis of CFS, at least during the first
5 years after onset of the disease.
Background
According to the guidelines of the United States Centers
for Disease Control and Prevention [1], chronic fatigue
syndrome (CFS) is defined as persistent fatigue, not sub-
stantially relieved by rest, and accompanied by other
specific symptoms for a minimum of 6 months. How-
ever, the etiology and pathophysiology of CFS remain
unclear. Homeostatic systems are assumed to be
impaired in CFS patients, leading to prolonged illness
and chronic fatigue symptoms [2,3]. Several lines of
study have addressed the possible causes of CFS. Psy-
chological disorders such as depression, viral infections,
autoimmune diseases, and prolonged stresses have all
been considered as potential candidates [4-6], although
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symptoms of CFS are still unclear. CFS is a highly het-
erogeneous and partly subjective illness, and no standard
laboratory test is currently available for the reliable diag-
nosis of CFS. These heterogeneity and lack of reliable
biomarkers result in lack of clues for exploring CFS
etiology and pathology. To prevent this vicious circle,
identifications of multiple objective biomarkers for CFS
have thus long been sought. In this regard, the present
study was aimed to establish a new biomarker for CSF.
Animal models of fatigue were established by Tanaka,
and this model showed a decrease ability to exercise [7].
In this model, we recently found that prolonged stress
caused various alterations in the brain and subsequent
changes in the endocrine organs and the brain [8,9].
The most notable changes occurred in the pituitary
gland. Prolonged stress resulted in overactivation of the
melanotrophs in the pituitary gland and their eventual
cell death. This overactivation and subsequent cell death
were caused by altered dopamine expression in a speci-
fic region of the hypothalamus, suggesting that molecu-
lar alterations in the brain can lead to the dysfunction
and further death of pituitary cells [9]. Significant
increases in plasma a-MSH levels were observed in this
animal model, and the removal of the pituitary gland
totally suppressed the increase induced by the stimulus.
These results suggested that hyper-activation of melano-
trophs induced the over-secretion of a-MSH from the
pituitary gland in response to continuous stress. We
therefore hypothesized that a similar increase in plasma
a-MSH levels reflecting the activation of melanotrophs
under chronic stress might occur in humans, especially
in patients suffering from persistent fatigue. In this
study, we therefore compared plasma a-MSH levels in
CFS patients with healthy controls during the first 10
years of the disease.
Methods
Study subjects
The study subjects included 55 patients with CFS (35.4
± 1.1 years old) and 30 age-sex-matched healthy con-
trols who did not complain of feeling fatigued and had
no illness, as healthy controls (36.1 ± 1.6 years old). The
CFS patients were diagnosed using the clinical criteria
proposed by Fukuda (1994) [1] and were treated at the
Osaka City University Hospital. Written informed con-
sent was obtained from each patient prior to the study.
The study was approved by the Ethical Committee of
Osaka City University.
Study protocol and methods
Venous blood was drawn between 9 and 10 am., after
fasting since the previous day. Following centrifugation,
plasma and serum fractions were frozen at -80°C until
assay. Plasma a-MSH levels were measured using a
commercial radioimmunoassay kit (Eurodiagnostica,
Malmö, Sweden). The minimum detectable concentra-
tion of a-MSH was 3.9 pg/mL and the intra- and inter-
assay coefficients of variation were 2.3% and 4.5%,
respectively. The cross-reactivity with other proopiome-
lanocortin peptides (adrenocorticotropic hormone
(ACTH) 1-24, ACTH 1-39, a-MSH and g-MSH) was <
0.002%. Previous tests have shown that a-MSH concen-
trations in plasma are stable over long periods when
properly stored at -80°C [10]. ACTH levels in plasma,
and cortisol and dehydroepiandrosterone sulfate
(DHEA-S) in serum were measured by the SRL Corp
[11,12]. The durations of CFS were determined as the
months from the first symptoms to the blood sampling
day. We excluded patients who had been suffering from
CFS for more than 10 years.
Statistical analysis
Results are expressed as means ± standard error of
mean (SEM). The differences between the CFS and
healthy groups were determined using Welch’s t-test.
Correlations were analyzed using Spearman’s rank test.
Correlation coefficients were obtained using Microsoft
Excel with the add-in software Statcel2 (Microsoft Co.
Japan). Differences among healthy controls, and patients
with shorter and longer durations of CFS were deter-
mined using Tukey’s test following one-way ANOVA.
p < 0.05 was considered statistically significant.
Results
The characteristics of the subjects are summarized in
Table 1. The mean plasma concentration of a-MSH in
the CFS group was 17.9 ± 1.0 pg/mL, which was higher
than that in the healthy group (14.5 ± 1.0 pg/mL, p =
0.02). The variation in levels was greater in the CFS
group than in the healthy group, as shown in Figure 1.
We therefore investigated the factors correlated with a-
MSH levels in the CFS group. There was a negative cor-
relation between plasma a-MSH levels and months of
CFS morbid period (with r = -0.28, p = 0.04, Figure 2
and Table 2). There were no correlations between a-
MSH and the following: gender, age, visual analog scale,
Table 1 Characteristics of the subjects
CFS Healthy
(n = 55) (n = 30)
Age (y) 35.4 ± 1.1 36.1 ± 1.6
Male 20 11
Female 35 19
a-MSH (pg/mL) 17.9 ± 1.0 14.5 ± 1.0*
Results are given as mean ± SEM.
*p < 0.05 between CFS and healthy controls (Welch’s t-test).
Shishioh-Ikejima et al. BMC Neurology 2010, 10:73
http://www.biomedcentral.com/1471-2377/10/73
Page 2 of 6performance status score, body mass index (BMI),
DHEA-S levels, ACTH levels, cortisol levels, blood pres-
sure, prescribed medicine, or physical or mental symp-
toms [11-15]. In particular no significant difference in
a-MSH levels between CFS patients with and without
depression was observed (p = 0.11 t-test). We investi-
gated the correlations between duration of CFS and
levels of other stress-responsive hormones. There were
no significant correlations between duration of CFS and
plasma ACTH, or serum cortisol or DHEA-S (p = 0.55,
p = 0.26 and p = 0.33, respectively) (Table 2).
CFS patients were divided into two groups: a shorter
CFS duration group (from 6-60 months) and a longer
CFS duration group (from 61-120 months). As shown in
Figure 3, the shorter duration group had significantly
higher levels of a-MSH than the healthy controls (p =
0.002, by one-way ANOVA; p < 0.01 by Tukey’st e s t ) .
The characteristics of the two CFS groups are shown in
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Figure 1 Concentrations of a-MSH in plasma of healthy control
and CFS patients. a-MSH levels in CFS patients were significantly
higher than in healthy controls (p < 0.05). The range of values in
the CFS group was wider than that in the control group.
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Figure 2 Correlations between a-MSH concentrations and
duration of CFS. A significant correlation was observed between
a-MSH and duration of the disease in CFS patients (r = -0.27, p <
0.05).
Table 2 Spearman’s rank correlation analysis of stress
hormones and CFS duration (months)
n r p-value
a-MSH 55 -0.28 0.04*
ACTH 43 -0.10 0.55
Cortisol 43 -0.17 0.26
DHEA-S 43 0.15 0.33
*p < 0.05
** p < 0.01
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Figure 3 Concentrations of a-MSH in CFS patients divided
according to duration of CFS and in healthy controls. The mean
a-MSH level in the 6-60-month group was significantly higher than
the levels in the other groups (p < 0.01 compared with the healthy
group, p < 0.05 compared with the 61-120-month group). Values
are given as means ± SEM.
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Page 3 of 6Table 3, which shows that there were no significant dif-
ferences in levels of other stress hormones between the
shorter and longer duration groups. In addition we
examined the differences of the onset symptoms among
patients, either the sudden or gradual, and found no sig-
nificant differences between.
Discussion
In this study, we demonstrated that plasma a-MSH
levels in CFS patients were significantly higher than
those in normal healthy controls, and that there was a
significant negative correlation between a-MSH concen-
trations and the duration of CFS. These results suggest
that a-MSH could be a biomarker for CFS in patients
who have suffered from the disease for less than 5 years.
I nc o n t r a s t ,w ew e r eu n a b l et oi d e n t i f ya n ys i g n i f i c a n t
correlation between the CFS morbid period and levels
of ACTH, cortisol or DHEA-S. This suggests that well
known stress markers such as ACTH and cortisol are
not suitable markers for CFS [11,16]. a-MSH also has
the advantage that its plasma levels remain relatively
stable, both in terms of daily variations [17], and in
terms of seasonal variations [18]. Furthermore, a-MSH
levels in healthy controls fall within a relatively narrow
range (Figure 1), as shown by both the current and pre-
vious reports [17-19]. Thus, 〈-MSH would have an
advantage as a biomarker to diagnose CFS in terms of
stability, because the level of 〈-MSH was not affected by
acute stress and rhythmicity.
Circulating a-MSH could originate from the pitui-
tary gland and/or blood cells. The results of experi-
ments using a continuous stress rat model suggested
that the a-MSH was produced by the pituitary gland.
Dopaminergic neurons located in A14 (the hypothala-
mic periventricular region) project their axons to the
intermediate lobe and suppress melanotroph activity
via dopamine production. In our previous study,
reduced dopamine synthesis in these neurons elicited
hyper-activation of melanotrophs. This was confirmed
by the application of a dopamine agonist, which sup-
pressed the secretion of a-MSH from the pituitary
gland [9]. Furthermore, removal of the pituitary gland
resulted in suppression of the stress-induced increase
of the plasma a-MSH, suggesting that the chronic
stress-induced increase of a-MSH originated from the
pituitary gland. These results suggest that dopamine
synthesis is suppressed in some hypothalamic neurons
in CFS patients, and melanotrophs may thus be hyper-
activated. Intriguingly, Sharpe et al. demonstrated an
increase in prolactin response in CFS, and suggested
the possibility that CFS patients could have an abnor-
mal dopamine neurotransmission [20]. Overall, these
results suggest that a disorder of the hypothalamic
dopaminergic neurons or dopamine neurotransmission
m i g h to c c u ri nC F Sp a t i e n t s ,a n dt h a tt h i sc o u l d
further affect pituitary hormone secretion. Although
the structure of the intermediate lobe is less clear
than that seen in rodents, melanotrophs are found in
the intermediate area of the human pituitary gland. It
thus seems likely that the increase in circulating a-
MSH in CFS patients originates from the pituitary
gland in response to persistent and prolonged stress.
However, some human studies have reported that
some blood cells in patients with sepsis and some
inflammatory diseases secrete a-MSH [21], and the
possibility that a-MSH is released by some blood cells
in CFS patients following prolonged stimulation can-
not be ruled out.
We found a negative correlation between a-MSH
levels and the duration of CFS. As the duration
increased, the a-MSH level fell to similar levels to that
seen in the healthy controls. This may be a result of
melanotroph dysfunction following prolonged stimula-
tion. In a rat model, melanotrophs subjected to continu-
ous stress for more than 5 days showed degenerative
features due to hyper-secretion of a-MSH, and the
raised a-MSH levels fell five days after stimulation [9].
Thus, melanotrophs in human with CFS are likely to
become exhausted and impaired by prolonged stress. It
is also possible that the melanotrophs become desensi-
tized following prolonged stimulation, or that the pro-
longed high level of a-MSH may activate an
unidentified feedback system from the periphery.
The functional significance of circulating a-MSH
remains unclear, though a-MSH has been shown to
have an anti-inflammatory function [17]. In vitro,l i p o -
polysaccharide-stimulated inflammatory cytokines were
suppressed by the application of a-MSH [22-24]. In
accordance with this in vitro study, increases in plasma
a-MSH have also been reported in some inflammation-
associated diseases, such as HIV [10] and sepsis [21].
Intriguingly, elevated a-MSH levels were observed parti-
cularly in non-progressive HIV patients and in sepsis
Table 3 Characteristics of the subjects divided according
to CFS duration
6-60 months 61-120 months
Age 33.6 ± 1.7 (n = 25) 36.9 ± 1.5 (n = 30)
Male 9 15
Female 16 15
BMI (kg/m
2) 21.4 ± 0.63 (n = 25) 21.1 ± 0.59 (n = 30)
a-MSH (pg/mL) 20.8 ± 1.2 (n = 25) 15.6 ± 1.4 (n = 30)*
ACTH (pg/mL) 29.3 ± 3.7 (n = 18) 23.44 ± 3.3 (n = 25)
Cortisol (mg/dL) 16.4 ± 1.6 (n = 18) 12.9 ± 1.2 (n = 25)
DHEA-S (mg/dL) 163.4 ± 16.5 (n = 18) 167.88 ± 15.7 (n = 25)
Results are given as mean ± SEM.
*p < 0.05 between 6-60-month group and 61-120-month group (Tukey’s test).
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Page 4 of 6patients with lower plasma tumor necrosis factor-a
(TNF-a) levels. These observations suggest that
increased a-MSH levels may have suppressed the
inflammatory responses and consequently inhibited the
progression of HIV and the increase in TNF-a.S o m e
CFS patients in the current study also had symptoms
such as slight fever, pharyngalgia and lymphadenopathy,
though no significant correlations between a-MSH
levels and these symptoms were observed (data not
shown). However in this study we could not conclude
that the increase of a-MSH was for the anti-inflamma-
tory function. In some literatures, increased levels of a-
MSH have also been demonstrated in patients suffering
from congestive heart failure (CHF) [19] and obesity
[14,15]. None of the patients in the current study had
CHF, and eight had BMIs of > 25. We were thus unable
to address the possible correlation between CFS and
CHF, and no correlation between a-MSH levels and
BMI was found in the patients examined. Consequently
it is hard to explain some functional significance in the
increase of a-MSH in CFS patients, and we could not
rule out a possibility that this was simply an empirical
association.
Currently an intriguing issue would be an association
between viral infections and a-MSH levels. Recently, a
link between the xenotropic murine leukemia virus-
related virus (XMRV) and CFS was reported and sug-
gested that XMRV infection may be a causal factor in
the pathogenesis of CFS [25,26]. Although this associa-
tion is currently conflicting and under debate, changes
of inflammatory cytokines and chemokines by XMRV
infection may lead to the increase of a-MSH levels. It
would be of interest to clarify the association between
XMRV infection and increase of a-MSH levels.
Although a-MSH could be a biomarker for CFS
within five years duration, the a-MSH level may be
higher in other fatigue related diseases such as insomnia,
sleep apnea and inflammatory diseases caused by virus
infections. Those points should be clarified in successive
studies near future.
Conclusions
In conclusion, increased plasma levels of a-MSH are
found in patients with CFS during the first 5 years of
the disease. Although raised a-MSH levels are also
observed in CHF, obesity, and inflammatory diseases
such as sepsis and HIV, all these diseases can be diag-
nosed and excluded as diagnoses in patients with CFS.
After exclusion of these other diseases, a-MSH has the
potential to act as a biomarker for CFS. Further studies
of fatigue-related diseases are needed to confirm its
potential and establish the reliability of a-MSH as a
marker of CFS.
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